Caitong International Asset Management Co. Ltd Increases Holdings in Hologic, Inc. $HOLX

Caitong International Asset Management Co. Ltd increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 193.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 414 shares of the medical equipment provider’s stock after acquiring an additional 273 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Hologic were worth $27,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC purchased a new position in Hologic during the second quarter worth approximately $26,000. Zions Bancorporation National Association UT purchased a new position in Hologic during the first quarter worth approximately $34,000. Cromwell Holdings LLC lifted its position in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares in the last quarter. Allworth Financial LP lifted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 216 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in Hologic during the first quarter worth approximately $42,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.88% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HOLX shares. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Leerink Partners raised their target price on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Evercore ISI set a $78.00 target price on Hologic and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $78.00 target price on shares of Hologic in a research note on Wednesday, October 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average price target of $79.23.

Hologic Trading Up 0.1%

Shares of NASDAQ HOLX opened at $73.99 on Monday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a fifty day simple moving average of $67.65 and a 200-day simple moving average of $64.03. The stock has a market capitalization of $16.46 billion, a PE ratio of 30.70, a PEG ratio of 2.54 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the firm posted $1.06 earnings per share. The company’s revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.